Jasper Therapeutics, Inc. (JSPR) · Nov 4, 2026 · Other events
1-for-30 reverse split — 1-for-30 ratio; approximately 1.11M shares after split
Jasper Therapeutics’ reverse split takes effect Friday, aiming to restore Nasdaq compliance while leaving its clinical pipeline and capital needs unchanged.
Jasper is a clinical-stage biotech advancing KP-104 in renal disease, briquilimab in transplant and mast-cell disorders, and KP-701 toward the clinic; its next substantive operating catalyst is interim KP-104 data expected in the fourth quarter of 2026.
This is a listing-compliance action, not a pipeline update. Jasper will execute the already-approved reverse split at a 1-for-30 ratio, effective November 6, 2026. 〔0〕 The move was anticipated: shareholders approved a 1-for-15 to 1-for-35 range on September 30 after Jasper had already disclosed a Nasdaq minimum-bid deficiency.
The split improves the company’s ability to address the $1 minimum-bid rule but does not strengthen the underlying business. Shares outstanding will fall from approximately 33.3 million to 1.11 million, while ownership percentages and the authorized share count remain essentially unchanged. 〔1〕 This is a mechanical adjustment intended to raise the quoted share price, not new funding, clinical progress, or value creation.
The remaining risk is that compliance is not fully secured. Jasper explicitly warns that the share price may not remain above $1.00, liquidity may decline, and the company may still fail other Nasdaq requirements. That matters because Jasper had also disclosed a separate stockholders’ equity deficiency, so the reverse split addresses only one part of its listing situation.
Bottom line: This confirms a previously telegraphed capital-structure repair. It may help preserve Nasdaq access, but it does not change Jasper’s clinical prospects, financing needs, or business trajectory.
KP-104 interim renal-basket data, fourth quarter 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!